Advertisement
U.S. markets closed

DaVita Inc. (DVA)

NYSE - NYSE Delayed Price. Currency in USD
138.05+1.20 (+0.88%)
At close: 04:00PM EDT
138.69 +0.64 (+0.46%)
After hours: 08:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close136.85
Open137.00
Bid137.78 x 900
Ask137.75 x 800
Day's Range136.96 - 138.14
52 Week Range71.51 - 141.54
Volume548,405
Avg. Volume895,860
Market Cap12.054B
Beta (5Y Monthly)1.03
PE Ratio (TTM)18.63
EPS (TTM)7.41
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est132.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
7% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for DVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DaVita Inc.
    Analyst Report: DaVita Inc.DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
    Rating
    Fair Value
    Economic Moat
    14 hours agoMorningstar
View more